Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Current Assets (2016 - 2025)

ProQR Therapeutics' Current Assets history spans 6 years, with the latest figure at $116.6 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 29.1% to $116.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $116.6 million, a 29.1% decrease, with the full-year FY2025 number at $116.6 million, down 29.1% from a year prior.
  • Current Assets hit $116.6 million in Q4 2025 for ProQR Therapeutics, down from $164.4 million in the prior quarter.
  • Over the last five years, Current Assets for PRQR hit a ceiling of $219.1 million in Q4 2021 and a floor of $87893.6 in Q1 2021.
  • Historically, Current Assets has averaged $147.9 million across 5 years, with a median of $154.8 million in 2022.
  • The widest YoY moves for Current Assets: up 220132.99% in 2022, down 49.73% in 2022.
  • Tracing PRQR's Current Assets over 5 years: stood at $219.1 million in 2021, then decreased by 28.06% to $157.6 million in 2022, then dropped by 17.4% to $130.2 million in 2023, then grew by 26.29% to $164.4 million in 2024, then fell by 29.1% to $116.6 million in 2025.
  • Business Quant data shows Current Assets for PRQR at $116.6 million in Q4 2025, $164.4 million in Q4 2024, and $130.2 million in Q4 2023.